AliveX Biotech Files IPO Prospectus Highlighting AI-Powered Multi-Omics Platform for Immune Decoding and Target Discovery

AliveX Biotech has been committed to decoding human immunity using AI and multi-omics, understanding the essence of biology from the ground up, and efficiently empowering the development of novel biomarkers and targets to address complex medical issues. The AliveX platform solution accelerates the discovery of biomarkers and targets and enhances the precision of therapeutic target screening through an innovative and efficient end-to-end technology platform. This significantly improves R&D efficiency and success rates, leading the way in the new paradigm of next-generation life science research and development.

AliveX Biotech possesses internationally leading AI and multi-omics interdisciplinary technical capabilities. The core team comes from top-tier research institutions and MNC pharmaceutical companies both in China and abroad, including Harvard, Oxford, Columbia University, UCSD, ETH, the Chinese Academy of Sciences, well-known tertiary hospitals, and internet giants, covering interdisciplinary elite talents in fields such as AI, systems biology, immunology, tumor immunology, clinical testing, and bioinformatics. Team members have published over a hundred papers in SCI core journals (such as Nature and Cell).

The company owns dozens of core technology independent intellectual property rights and has obtained national high-tech enterprise certification. It has established a medical testing laboratory and multi-omics experimental platform in Beijing, including flow cytometry detection platform, MSD detection platform, proteomics, metabolomics, and transcriptomics, among other technical platforms, and possesses multi-omics joint data analysis capabilities. Currently, the company has established in-depth cooperative relationships with many top clinical institutions, scientific research institutes, and innovative pharmaceutical enterprises both domestically and internationally. It has also built a closed-loop R&D ecosystem for industry-university-research collaboration that spans basic research, applied research, clinical transformation, and interdisciplinary technological innovation. The company now has five office locations worldwide (Shanghai, Beijing, Oxford, Zurich, Copenhagen) and has received joint investments from Five Source Capital, Xinyuan Capital, and K2 Venture Partners.

AliveX Platform Solutions
AliveX Platform Solution Leads the New Paradigm of Next-Generation Biomarker and Target Research through an Innovative and Efficient End-to-End R&D Process.

Figure: From the official website of AliveX Biotech

AliveX Biotech has innovatively developed a world-leading AI + systems immunology technology platform, which includes a multi-omics experimental platform and a bio-computation platform. Based on systems biology technology, the platform acquires, generates, and analyzes multi-omics data, utilizing personalized mechanism modeling and AI to map the immune landscape. It comprehensively analyzes the complex human immune system from multiple dimensions, accelerating the discovery of biomarkers and targets while enhancing the precision of therapeutic target screening, significantly improving R&D efficiency and success rates.

For immune-related diseases such as oncology and autoimmune conditions, the AliveX platform provides AI-powered immunology-enhanced research services or co-development to biotech companies in innovative drug development, clinical research organizations, and research institutes, offering highly customized biomarker or target discovery solutions.

[Contact Information]
• Contact Email: contact@alivexbiotech.com
• Business Address: 6th Floor, Building B, Phase I, Fenglin International Center, No. 388 Fenglin Road, Xuhui District, Shanghai, China
• Official Website: http://alivexbiotech.com
• Official WeChat QR Code:

Editor: Baiji